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Background—Prior to introduction of tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV), 3-
drug antiretroviral treatment (ART) was associated with increased adverse birth outcomes when 
used for prevention of mother-to-child HIV transmission (PMTCT) in Botswana.
Methods—We extracted obstetric records from all women at the 2 largest maternities in 
Botswana from 2009-11 when Botswana National Guidelines recommended ZDV from 28 weeks 
gestational age (GA) for CD4 ≥350 and ART for CD4 <350, and again in 2013-14 after 
implementation of TDF/FTC/EFV for PMTCT regardless of CD4 or GA. We compared use of 
TDF/FTC/EFV in pregnancy with other 3-drug ART regimens, and with initiation of ZDV, among 
women with similar CD4 cell counts. Outcomes included small for gestational age (SGA), preterm 
delivery (PTD) (<37 weeks GA), and stillbirths (SB).
Results—Among 9445 HIV-infected women delivering during the study period, 170 were on 
TDF/FTC/EFV at conception and 1468 initiated TDF/FTC/EFV during pregnancy. Adverse birth 
outcomes were high overall (3% SB, 21% PTD, and 18% SGA), and among women receiving 
TDF/FTC/EFV (3% SB, 22% PTD and 12% SGA). There was no difference in PTD or SB among 
women initiating TDF/FTC/EFV compared with ZDV or other 3-drug ART, but initiating 
TDF/FTC/EFV was associated with fewer SGA infants than other 3-drug ART (aOR 0.4, 95% CI 
0.2,0.7).
Conclusions—Adverse birth outcomes remain high among HIV–infected women. 
TDF/FTC/EFV was at least as safe as other ART, and associated with fewer SGA infants when 
initiated during pregnancy. Larger studies are needed to evaluate birth outcomes and congenital 
abnormalities among women on TDF/FTC/EFV at conception.
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Introduction
Expansion of programs to provide antiretroviral (ARV) medication during pregnancy has 
dramatically reduced mother to child HIV transmission (MTCT) in low- and middle-income 
countries [1]. Further reductions in MTCT are expected as countries rapidly adopt universal 
3-drug ART for all pregnant and breastfeeding women (WHO Option B), including those 
opting for life-long ART continuation beyond the PMTCT period (WHO Option B+) [1,2]. 
TDF/FTC/EFV is recommended by WHO as the preferred regimen for prevention of MTCT 
(PMTCT) because of the simplicity of the regimen, minimization of drug-drug interactions, 
and harmonization with the adult HIV treatment guidelines [3-12]. However, data for birth 
outcomes with TDF/FTC/EFV remain insufficient [13-22].
Prior to 2012, National PMTCT guidelines in Botswana recommended 3-drug ART 
(Zidovudine/Lamivudine/Nevirapine, ZDV/3TC/NVP) for women with CD4 cell count 
≤350 cells/mm3 and ZDV-alone from 28 weeks gestational age (GA) for women with CD4 
cell count >350 cells/mm3. In 2012, Botswana rolled out new national HIV treatment 
guidelines that recommended TDF/FTC/EFV as the preferred regimen for adults with CD4 
≤ 350 cells/mm3 and for all HIV-infected pregnant and breastfeeding women [23]. This 
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study evaluated adverse birth outcomes among women on TDF/FTC/EFV during pregnancy, 
and the potential impact of TDF/FTC/EFV on implementation of PMTCT.
Methods
Study Population
From May 2009-April 2011 and from April 2013-April 2014, we abstracted data from 
obstetric records of women who delivered live born or stillborn infants at the two largest 
public maternity wards in Botswana, Princess Marina Hospital (PMH) in Gaborone and 
Nyangabgwe Referral Hospital (NRH) in Francistown. These sites delivered almost 25% of 
all births in the country [24]. We excluded women who delivered prior to arrival to the 
hospital, women who were transferred from other hospitals after delivery, and women who 
delivered at gestational age (GA) < 24 weeks. Detailed information was only recorded on 
the first-born infant in the case of a pregnancy with multiple gestations during the study.
During the study period, HIV-infected women received PMTCT care from Botswana 
government providers and according to Botswana National HIV guidelines. Botswana 
Ministry of Health recommended routine HIV testing of all pregnant women and for citizens 
of Botswana the government provided free antenatal care services, HIV testing, infant 
formula and ARVs. In 2009-2011, HIV-infected women not already on ART were eligible 
to start ZDV at 28 weeks gestation if their CD4 cell count was >350 cell/mm3 and eligible to 
receive 3-drug ART (generally ZDV/3TC/NVP) if their CD4 cell count was ≤ 350 cell/mL. 
Some women across all CD4 cell counts also accessed ZDV/3TC/LPV/r as part of a 
government pilot program for 3-drug universal PMTCT. During this time period, 
TDF/FTC/EFV was avoided in women of childbearing age due to concerns for neural tube 
defects in the event of pregnancy. New Botswana National Guidelines were implemented in 
2012, and during the 2013-2014 study period TDF/3TC/EFV was recommended for all HIV-
infected adults with CD4 cell count ≤ 350 cells/mm3, and for pregnant women regardless of 
CD4 cell count. Women on ART at conception continued their ART regimen and were not 
switched to TDF/FTC/EFV.
Data Extraction
Data was abstracted from maternal obstetric records (covering outpatient antenatal care and 
inpatient care during labor and delivery) at the time of discharge from the postnatal ward. 
Abstracted information included maternal demographics, maternal medical history, self-
reported alcohol and tobacco use, results of HIV testing, laboratory values measured in 
pregnancy (hemoglobin, rapid plasma regain [RPR], blood type, RH factor), medications 
taken at the time of conception, maternal diagnoses during pregnancy, vitamins and 
antibiotics prescribed during pregnancy, and infant outcomes. Diagnoses were recorded as 
per documentation of the treating physician or midwife, except for maternal anemia which 
was defined as hemoglobin ≤10 g/dL and maternal hypertension which was defined as 
systolic blood pressure ≥140 or diastolic blood pressure ≥90 in pregnancy. The estimated 
GA included in the obstetric record was used for analyses and if missing, GA was calculated 
using LMP. Antenatal clinic nurses estimated GA by date of LMP in most cases, but used 
fundal measurements or ultrasound if LMP was unknown. For HIV-infected women, we 
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collected the date of HIV diagnosis, most recent CD4 cell count, and antiretroviral history 
(including ARV start date, regimen and any switch or discontinuation during pregnancy). 
Infant data were abstracted from the medical record, and included gender, birth weight, 
delivery complications and admission to the neonatal unit.
Exposure and Outcome Definitions and Statistical Analysis
The primary exposure was use of any antiretroviral medication during pregnancy. 
Antiretroviral use was categorized as ART initiated prior to pregnancy (ART at conception), 
ARVs initiated during pregnancy, and no antiretroviral drugs received prior to the onset of 
labor or induction. Women who switched or terminated their ARV regimen were excluded 
from analysis except if they initiated ZDV and were switched to ART, in which case 
regimen at delivery was used. Sensitivity analysis was performed including all women who 
changed regimens during pregnancy, in which case conception regimen was used for those 
continuing in pregnancy and delivery regimen was used in women initiating ARVs. ZDV 
and NVP given during labor and delivery, when it was too late to be a causative factor in the 
birth outcome, were not considered in the analysis.
The 4 primary outcomes were SB, PTD, very preterm delivery (vPTD) and SGA. SB was 
defined as fetal death (APGAR 0,0,0) and included both macerated and fresh stillbirth; 
preterm delivery was a birth at <37 weeks gestational age; very preterm delivery was a birth 
at <33 weeks of age. An infant was considered SGA if below the 10th percentile of 
birthweight by gestational age using norms specific to infants born in Botswana [25]. 
Because norms were only available for gestational ages 30-40 weeks, infants delivered 
outside of this range were excluded from the SGA analysis. A second analysis was 
performed defining SGA using World Health Organization norms which had no gestational 
age restrictions[26].
To limit lead-time bias when comparing outcomes among women initiating ARVs in 
pregnancy, we restricted the analysis to women who initiated ARVs prior to 30 weeks GA 
and who delivered at or after 30 weeks GA. To compare PMTCT regimens offered within 
similar CD4 cell count strata during the different PMTCT eras, we restricted analyses of 
ZDV vs. TDF/FTC/EFV to women with CD4 >350 cells/mmm3 and other 3-drug ART vs. 
TDF/FTC/EFV to women with CD4 ≤350 cells/mm3.
Among women on ART at conception, we considered ‘other ART’ as all 3-drug ARV 
regimens with exception of the single-pill co-formulation TDF/FTC/EFV or the 2-pill 
formulation of TDF/FTC (Truvada) plus EFV. For analysis of both conception ART and 
intitiation of ARVs, ART without a specified regimen was considered to be non-Atripla 3-
drug ART in 2009-11 (as TDF/FTC/EFV was not used) but was considered to be unknown 
ART in 2013-14 as there was no way to discern if it was TDF/FTC/EFV. Sensitivity 
analysis were performed that included and excluded women on ART without a specified 
regimen.
Unadjusted and adjusted logistic regression analyses were used to evaluate the association of 
ART use and the 4 primary outcomes. Given the link between immunodeficiency and 
adverse outcomes in prior studies [26-28] CD4 cell count was included as a covariate in all 
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analyses. The remainder of covariates in adjusted analyses were determined through 
stepwise selection with retention of variables with p<0.2. Statistical analyses were 
performed using SAS, version 9.3 (SAS institute, Cary, NC). All reported p-values are based 
on a 2-sided test.
Ethical Approval
Approval was granted by human subjects committees in Botswana and at the Harvard 
School of Public Health.
Results
There were 32,583 birth outcomes recorded, 20,057 (62%) at PMH and 12,526 (38%) at 
NH, representing almost 25% of all births in Botswana during surveillance periods [23]. In 
2009-2011, 20,716 (64%) records were abstracted, and in 2013-2014, 11,867 (36%) were 
abstracted. In total, 31,463 (97%) women had a known HIV status, and 9445 (30%) were 
HIV positive.
Differences in demographics, HIV status, and birth outcomes by time period are shown in 
Table 1. Improved PMTCT indicators were seen in 2013-2014 compared with 2009-2011. In 
2013-14, women were more likely to be tested for HIV (99 vs. 95%, p<0.0001) and more 
likely to receive ARVs during pregnancy (88% vs. 84%, p<0.0001) (Table 1). The 
proportion of women receiving fewer than 4 weeks of ARVs prior to delivery decreased 
from 25% in 2009-2011 to 17% in 2013-2014. Almost 3 times as many women initiated 
ARVs before 28 weeks GA in 2013-14 compared with 2009-2011 and the difference was 
even greater among those with low CD4 cell counts (75% vs. 31%, p<0.0001).
During the entire study period, 2602 (28%) HIV-infected women were on ART at 
conception, 5247 (56%) initiated ARVs during pregnancy, 1390 (15%) received no ARVs 
during pregnancy and 206 (2%) received ARVs during pregnancy but the timing was 
unknown. CD4 cell count was known in 4022 (43%). Median CD4 cell count was 395 
cells/mm3 overall, and differed by time period (Table 1) and ARV exposure category (Table 
2).
Adverse birth outcomes were high among HIV-infected women (SB 5%, PTD 27%, vPTD 
10%, SGA 19%), and lower among HIV-uninfected women (SB 3%, PTD 19%, vPTD 6%, 
SGA 10%)(p < 0.0001 for all comparisons). Among HIV-uninfected women the prevalence 
of all adverse birth outcomes was the same in 2009-11 and in 2013-14.
Women Initiating Antiretrovirals in Pregnancy
Data were collected on 5247 women who initiated ARVs in pregnancy: 1468 (28%) initiated 
TDF/FTC/EFV; 778 (15%) initiated other 3-drug ART; 2923 (56%) initiated ZDV; and 78 
(1%) initiated unspecified ARVs. Twenty-eight (1%) women initiating ARVs either 
switched regimens (N=19) or had unknown regimen switch status (N=9) during pregnancy 
and were excluded from further analysis. Other 3-drug ART regimens included 
ZDV/3TC/NVP (36%), unspecified ART in 2009-11 (38%) which was almost exclusively 
ZDV/3TC/NVP given National ARV guidelines, ZDV/3TC/Lopinavir/ritonavir (19%), 
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TDF/FTC/NVP(4%), and other ART (3%). Pregnancy CD4 cell count was available in 59%, 
and 70% started ARVs by 30 weeks GA. Median CD4 cell count by exposure categories are 
shown in Table 3.
Overall, adverse birth outcomes occurred in 1167 (36%) of women who initiated ARVs 
before 30 weeks GA and adverse outcomes were less common among women initiating 
TDF/FTC/EFV than women initiating any other ARV (aOR 0.4 95% CI 0.3,0.6) (Table 2). 
Among women with CD4 ≤350 cells/mm3 those who initiated TDF/FTC/EFV had fewer 
SGA infants (aOR 0.5, 95% CI 0.3,0.8) and no significant differences in PTD (aOR 0.5, 
95%CI 0.2,1.2) or SB (aOR 0.1, 95%CI 0.01,1.0) compared with women initiating other 3-
drug ART in pregnancy. Among women with CD4 >350 cells/mm3, women initiating 
TDF/FTC/EFV had fewer SGA infants (aOR 0.7, 95%CI 0.5,1.0) but this was not 
statistically significant and there was no difference in PTD (aOR 1.1, 95%CI 0.6,2.1) or SB 
(aOR 0.9, 95% CI 0.4, 2.1) compared with initiating ZDV. Compared with women initiating 
any other ARV (ART or ZDV) without CD4 restriction, TDF/FTC/EFV had fewer SGA 
infants (aOR 0.5, 95% CI 0.4,0.7) and no statistically significant difference in PTD (aOR 
0.7, 95%CI 0.5,1,1) or SB (aOR 0.6, 95% CI 0.3,1.3) (Table 3).
Women Continuing Antiretroviral Therapy in Pregnancy
Data were collected on 2602 women on ART at conception; 170 (7%) were on TDF/FTC/
EFV, 669 (26%) were on ZDV/3TC/NVP, 287 (11%) were on TDF/FTC/NVP, 61 (2%) 
were on TDF/FTC/LPV/r, 49 (2%) were on ZDV/3TC/LPV/r, 977 (38%) were on other non-
TDF/FTC/EFV regimens, and 389 (15%) were on unknown ART regimens. Thirty-five 
(1%) of these women switched ART during pregnancy and 7 (0.1%) had unknown ART 
switch status and were excluded from further analysis. Pregnancy CD4 cell count was 
available in 613 (24%) and was similar among women on TDF/FTC/EFV compared with 
women on other 3-drug ART (475 vs. 426 cells/mm3, p=0.7).
Adverse birth outcomes occurred in 1085 (50%) of all women on ART at conception; 6.3% 
SB, 31.2% PTD, 11.7% vPTD and 22.6% SGA (Table 4). Compared with women on other 
3-drug ART at conception, women on TDF/FTC/EFV at conception had fewer overall 
adverse outcomes (33% vs. 51%), fewer SB (4.9% vs. 6.4%), and fewer infants SGA (8% 
vs. 24%) but none of these findings were statistically significant in adjusted analysis (Table 
4). Rates of PTD (28% vs 32%) and vPTD (10% vs. 12%) were similar among women on 
TDF/FTC/EFV at conception compared with women on other ART at conception. Results 
did not differ if women who changed ART during pregnancy were included in the analysis.
Tolerability of TDF/FTC/EFV in pregnancy
Among women who initiated ARVs during pregnancy, only 1 (0.06%) woman initiating 
TDF/FTC/EFV changed regimens compared with 18 (2%) of women initiating other 3-drug 
ARVs (p<0.0001). Five (3%) women on TDF/FTC/EFV at conception changed regimens 
during pregnancy (only 1 was after guidelines were updated), compared with 30 (1%) 
women on other 3-drug ART at conception.
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Discussion
We performed the first study of birth outcomes within a national program using 
TDF/FTC/EFV as the recommended regimen for the prevention of mother to child 
transmission of HIV. We confirmed earlier findings from Botswana that SB, PTD, vPTD 
and SGA were more common in HIV-infected women than in HIV-uninfected women and 
also that women on ART from conception had particularly high rates of all adverse 
outcomes [15]. However, we found no increased risk of any adverse birth outcome with the 
use of TDF/FTC/EFV when initiated during pregnancy or started prior to conception when 
compared with other commonly used PMTCT regimens, including ZDV-alone. We also 
identified that initiation of TDF/FTC/EFV during pregnancy was associated with fewer SGA 
infants when compared with women initiating other 3-drug ART. TDF/FTC/EFV was well 
tolerated in pregnancy.
Our finding that there was no increased risk of adverse birth outcomes among women 
initiating TDF/FTC/EFV in pregnancy compared with women initiating ZDV-monotherapy 
differs from most recent studies that compare initiation of ART with initiation of ZDV in 
pregnancy (Table 5) [15,18,30-33]. Unlike our study, prior studies included few women on 
EFV-based ART, suggesting the possibility that EFV could have fewer adverse effects at the 
placental level than either NVP or PIs, though additional studies will be needed to confirm 
this finding. However, our findings are reassuring in light of randomized data from a large 
RCT (PROMISE) that found more severe adverse birth outcomes among women initiated on 
TDF/FTC/LPV/r compared with CBV/3TC/LPV/r in pregnancy [30]. Our finding that TDF 
was not associated with adverse birth outcomes when combined with EFV adds support to 
the argument that a drug interaction between TDF and LPV/r may have contributed to 
adverse birth outcomes in PROMISE [34-36].
Our finding that women exposed to TDF/FTC/EFV had fewer SGA infants than women 
exposed to other ARVs was unexpected given previous concern that TDF may be associated 
with decreased infant growth[37]. TDF/FTC/EFV exposure primarily occurred in the 
2013-14 data collection period, so it is possible that changes in SGA over time could explain 
this finding. However, this seems unlikely as there was no difference in SGA among HIV-
uninfected women between the two time periods, which would be expected if SGA were 
declining due to other factors in obstetric care or environment in Botswana. There were no 
differences in gestational age at delivery between these two time periods in any ARV-
exposure group, so differences in measurement of GA that could lead to differences in SGA 
between the time periods were an unlikely source of bias. Also, the effect estimates were 
almost identical when using 2 different scales to define SGA—WHO birthweight-for-GA 
norms and birthweightfor-GA norms specific to Botswana.
This study has similar overall rates of all adverse outcomes as previous studies in 
Botswana[15] and these rates are strikingly high. Among women on ART at conception, half 
(49.9%) experience an adverse birth outcome, including 10% born before 33 weeks 
gestation and more than 5% stillborn. Although there have been significant improvements in 
under-5 mortality globally, neonatal mortality has not decreased at a similar pace and the 
WHO now considers addressing neonatal mortality a top priority [38, 39]. As preterm 
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delivery is the most common cause of neonatal mortality, it is critical to understand the 
underlying mechanism associating HIV, ART and adverse birth outcomes. Further 
exploration of current hypotheses linking ART to chronic placental insufficiency [22], 
decreased progesterone [40,41] and immunomodulatory dysfunction, (particularly Th1/Th2 
shift [42]) are needed.
Our study has several strengths, including the large sample size and reasonable 
generalizability to the overall population since > 95% of women deliver in a hospital 
(including 25% of all births in Botswana at these 2 hospitals). There were few women with 
unknown HIV status, a high proportion of women received ARVs in pregnancy, and a large 
number of women were on ART prior to conception. However, there were potential 
limitations, including the fact that PMH and NRH are referral hospitals, and referral of high-
risk pregnancies to these maternities may overestimate adverse birth outcomes in Botswana. 
A relatively high number of women were missing CD4 cell counts, particularly among 
women in the second surveillance period (2013-14) (when CD4 cell counts were not needed 
in order to initiate ART). Many variables were self-reported, including prior medical history, 
alcohol and tobacco use, and routine laboratory data, particularly RPR testing for syphilis, 
was inconsistently performed and reported. The gestational age of infants was estimated 
based primarily on LMP, which is not as reliable as early ultrasound. All information was 
abstracted from the medical records and we cannot confirm the accuracy of the recorded 
information. However, the maternity obstetric card is standardized throughout Botswana and 
prompts midwives to record specific information, and we found that information from the 
obstetric record was very complete. We do not believe there was any differential data entry 
error by ART regimen that would systematically bias the results of this large study.
Given the observational nature of our study, causation cannot be established and multiple 
sources of bias are possible. We tried to minimize lead-time bias by comparing only groups 
that had the same “at risk” time for an outcome, limiting comparisons of women on 
TDF/FTC/EFV at conception to women on other ART at conception and restricting the 
analysis of women initiating ARVs in pregnancy to those who did so prior to 30 weeks and 
only including outcomes occurring at or after 30 weeks. This was particularly important as it 
was protocol for ZDV to be initiated at 28 weeks of gestation, while there was no restriction 
on the initiation of TDF/FTC/EFV which occurred at a median of 21 weeks. Since 
TDF/FTC/EFV was initiated in women of all CD4 cell counts but 350 CD4 cells/mm3 was 
used as a threshold for ZDV vs. other ART regimens, we tried to minimize bias by 
indication by restricting analysis of women initiating ARVs to appropriate CD4 strata. We 
also tried to minimize bias by confounding through adjusted analysis including covariates 
previously found to be associated with poor infant outcomes and using separate logistic 
regression models for each outcome as they may have different risk factors and different 
mechanisms. However, our associations could still be biased by unmeasured confounding, 
particularly as one CD4 cell count in pregnancy was the only measure of immune status 
available, and it is possible that nadir CD4 cell count, trend in CD4 cell count in pregnancy, 
or viral load might explain some differences.
In conclusion, this study provides reassuring observational data that implementing PMTCT 
programs with universal TDF/FTC/EFV is unlikely to worsen rates of SB, PTD and SGA 
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and may be associated with a decreased risk of SGA. The potential decrease in both overall 
adverse events and SGA with TDF/FTC/EFV needs to be confirmed by larger studies, and 
studies powered to evaluate potential associations between neural tube defects and 
TDF/FTC/EFV are also needed. This study also highlights the very high rates of adverse 
birth outcomes among HIV-infected pregnant women. Further understanding of the risk 
factors and mechanisms underlying poor outcomes in order to design appropriate 
interventions is a crucial step for decreasing neonatal mortality rates worldwide.
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Table 1
Baseline characteristics, HIV status and Birth Outcomes by Data Collection Period
HIV-Uninfected HIV-Infected
2009-2011 2013-2014 2009-2011 2013-2014
Maternal Characteristics
Age (years) 25.3yrs 25.7yrs 28.9yrs 30.2yrs
Unmarried 85.5% 82.3% 87.5% 87.4%
None/Primary Education 7.3% 5.4% 15.2% 11.3%
No Salary 49. 5% 59.7% 51.6% 54.1%
Non-Citizen 12.9% 8.2% 9.2% 7.0%
Any Medical History 12.6% 13.7% 17.4% 19.5%
Hypertension in pregnancy 16.8% 16.7% 19.1% 17.5%
Anemia in pregnancy 35.9% 25.8% 59.0% 48.1%
Obstetric Characteristics
Primiparous 48.1% 45.5% 20.6% 15.9%
Grand Multiparous (Gravida≥ 5) 5.6% 6.4% 13.5% 18.0%
Received NO prenatal care 4.1% 3.1% 5.7% 4.8%
Median gestational age 39 [37,40] 39 [37,40] 38 [36,40] 38 [36.40]
Mean birthweight 2992g 2992g 2775g 2781g
Birth Outcomes
Stillbirth 2.7% 2.7% 4.9% 4.8%
Preterm Delivery 19.4% 18.5% 27.7% 28.0%
Very Preterm Delivery 6.2% 6.7% 10.3% 10.8%
Small for Gestational Age 12.2% 12.6% 26.8 17.6%
PMTCT Program Characteristics
Unknown HIV status n/a n/a 4.7% 1.2%
No ARVs during Pregnancy 16.1% 12.3%
Initiated ARVs <4wks prior to delivery 24.7% 17.0%
Initiated ARVs <28wks GA 22.0% 59.8%
Initiated ARVs <28wks GA and CD4 <350 31.4% 75.3%
Days between HIV diagnosis and initiation of ARVs (mean) 65 39
Immunologic Profile
Proportion with CD4 cell count recorded n/a n/a 44.8% 38.6%
Median CD4 cell count 388 415
Median CD4 cell count among women initiating ARVs by 30 weeks GA 391 391
Median CD4 cell count among women on ART at conception 388 500
Median CD4 cell count among women on no ARVs during pregnancy 345 365
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Table 4
Adverse Birth Outcomes among women on ART at Conception
TDF/FTC/EFV at Conception 
N=165
Other 3-drug ART at Conception 
N=2006
OR (95% CI) aOR (95% CI)
Stillbirth 8 (4.9%) 128 (6.4%) 0.7 (0.4,1.6) 0.4 (0.1,2.9)ˆ
Preterm 47 (28%) 631 (31%) 0.9 (0.6, 1.2) 0.9 (0.3, 2.9)#
Very Preterm 17 (10%) 236 (12%) 0.9 (0.5, 1.5) 0.9 (0.1, 8.0)@
SGA
Botswana norms 14 (8%) 476 (24%) 0.3 (0.2,0.5) 0.4 (0.1,1.4)∼
WHO norms 22 (13%) 636 (32%) 0.3 (0.2,0.5) 0.3 (0.1, 1.0)∼
Any Adverse Outcome+ 55 (33%) 1030 (51%) 0.5 (0.4, 0.7) 0.5 (0.1, 1.2)*
Analysis excludes women with unknown ART regimen at conception (N=389), women who changed ART during pregnancy (N=34) and women 
who had unknown change of ART (N=3)
+Any adverse outcome is defined as any SB, PTD or SGA, but is less than the sum of the 3 outcomes because of overlap between PTD and SGA.
ˆ
adjusted for hypertension and CD4 cell count <250
#
adjusted for hypertension, anemia, low weight and CD4 cell count <250
@
adjusted for anemia, low weight and CD4 cell count <250
∼
adjusted for maternal age, education, employment status, anemia, and CD4 cell count<200
*
adjusted for any anemia, maternal age, low maternal weight, CD4 cell count <250
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